Imaging Guided Patient Selection for Interventional Revascularization Therapy (START)
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The START Trial: Clinical Outcome in Acute Stroke Treatment After Imaging Guided Patient Selection for Interventional Revascularization Therapy|
- Functional outcome as defined by a mRS of 0-2 at 90 days post-procedure [ Time Frame: At 90 days post-procedure ] [ Designated as safety issue: No ]
- Angiographic assessment of vessel patency as measured by TIMI and modified TICI scores at immediate post-procedure [ Time Frame: At immediate post-procedure ] [ Designated as safety issue: No ]
- Procedural serious adverse events during the procedure [ Time Frame: During the procedure ] [ Designated as safety issue: Yes ]
- Good neurological recovery post-procedure as defined by a 10 points or more improvement on the NIHSS at Discharge [ Time Frame: At Discharge ] [ Designated as safety issue: No ]
- Incidence of symptomatic and asymptomatic hemorrhage based on the ECASS criteria and patient neurological status within 24 hours of the procedure [ Time Frame: Within 24 hours of the procedure ] [ Designated as safety issue: Yes ]
- All cause mortality at 90 days post-procedure [ Time Frame: At 90 days post-procedure ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2009|
|Study Completion Date:||September 2016|
|Primary Completion Date:||September 2016 (Final data collection date for primary outcome measure)|
|Experimental: Penumbra Device Arm||
Device: Penumbra System
The Penumbra System is used to revascularize clotted cerebral blood vessels.
Study Title: The START Trial: Clinical Outcome in Acute Stroke Treatment after Imaging Guided Patient Selection for Interventional Revascularization Therapy
Study Objective: The objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom onset and with a known core infarct volume at admission. The data will also be used to determine if there is a correlation between infarct volume and functional outcome at 90 days post-procedure. Safety is defined by the procedural serious adverse events, and effectiveness is defined by the rate of revascularization (TIMI 2-3/TICI 2a-3) and good functional outcome. Good functional outcome is defined by a modified Rankin scale (mRS) score of 2 or less at 90 days post-procedure. Core infarct volume at admission will be assessed by computed tomography perfusion (CTP), computed tomography angiography (CTA) or magnetic resonance DWI scans. The core infarct volumes will be sub-grouped by <50cc, 50-100cc and >100cc to determine the correlation with patient functional outcome.
Study Design: A prospective, single arm, multi-center trial. Up to 200 patients at up to 45 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis.
Patient Population: Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with a known imaging-defined infarct volume will be enrolled for interventional treatment by the Penumbra System to achieve revascularization of the target vessel territory.
Indication: The Penumbra System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset.
Sample Size Justification: Up to 200 subjects will be enrolled in order to obtain up to 150 evaluable patients. Assuming a post-procedure angiographic success (TIMI 2-3/TICI 2a-3) rate of 80% (120/150), the expected two-sided exact binomial 95% confidence interval is (72.7%, 86.1%). Assuming a 90-day mRS success (mRS 0-2) rate of 30%, the expected two-sided exact binomial 95% confidence interval is (22.8%, 38.0%). Additionally, the study results will be used for sample size estimates for a potential future randomized, concurrent controlled trial.
Core Laboratory and Clinical Event Committee An independent Core Lab will review and score all imaging scans for infarct volume, TIMI, TICI and ICH. A Clinical Event Committee will adjudicate all Serious Adverse Events for severity and causality (disease-, procedure-, drug-, or device-relatedness.
Study Rationale: Use of interventional revascularization techniques offer several potential clinical benefits by improving cerebral perfusion to the target vascular territory in certain patients. The validation of a simple, pragmatic, and executable image guided patient selection paradigm may identify a cohort of acute stroke patients who will benefit from interventional treatment by the Penumbra System and in whom revascularization as a treatment for acute stroke will be indicated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00963989
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston,, South Carolina, United States, 29425|
|Study Director:||Siu P Sit, PhD||Penumbra Inc.|